The Inclusion Body Myositis (IBM) drugs in development market research report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Inclusion Body Myositis (IBM). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued products.

GlobalData tracks 12 drugs in development for Inclusion Body Myositis (IBM) by ten companies/universities/institutes. The top development phase for Inclusion Body Myositis (IBM) is preclinical with seven drugs in that stage. The Inclusion Body Myositis (IBM) pipeline has 12 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Inclusion Body Myositis (IBM) pipeline products market are: Orphina Biotechnology, Alzheon and Nobelpharma.

The key targets in the Inclusion Body Myositis (IBM) pipeline products market include Bifunctional UDP N Acetylglucosamine 2 Epimerase/N Acetylmannosamine Kinase (UDP GlcNAc 2 Epimerase/ManAc Kinase or UDP N Acetylglucosamine 2 Epimerase or N Acetylmannosamine Kinase or GNE or EC 3.2.1.183 or EC 2.7.1.60), Amyloid Beta A4 Protein (ABPP or APPI or Alzheimer Disease Amyloid Protein or Amyloid Precursor Protein or Amyloid Beta Precursor Protein or Cerebral Vascular Amyloid Peptide or Prea4 or Protease Nexin II or APP), and Glucagon Like Peptide 1 Receptor (GLP1R).

The key mechanisms of action in the Inclusion Body Myositis (IBM) pipeline product include Bifunctional UDP N Acetylglucosamine 2 Epimerase/N Acetylmannosamine Kinase (UDP GlcNAc 2 Epimerase/ManAc Kinase or UDP N Acetylglucosamine 2 Epimerase or N Acetylmannosamine Kinase or GNE or EC 3.2.1.183 or EC 2.7.1.60) Activator with two drugs in Preclinical. The Inclusion Body Myositis (IBM) pipeline products include two routes of administration with the top ROA being Oral and six key molecule types in the Inclusion Body Myositis (IBM) pipeline products market including Gene Therapy, and Small Molecule.

Inclusion Body Myositis (IBM) overview

Inclusion body myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

For a complete picture of Inclusion Body Myositis (IBM)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.